Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NY-ESO-1 ISCOMATRIX vaccine (Ludwig Cancer Research)
- Development stage
- Unknown
- Lead developer
- Ludwig Cancer Research
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
NY-ESO-1 ISCOMATRIX vaccine is a cancer immunotherapy developed by the Ludwig Institute for Cancer Research in collaboration with CSL Limited. The vaccine comprises a full-length recombinant NY-ESO-1 protein, a cancer-testis antigen frequently expressed in advanced melanomas but absent in most normal tissues. It is formulated with ISCOMATRIX, a proprietary saponin-based adjuvant designed to enhance the magnitude and breadth of the immune response. Administered intramuscularly, the vaccine aims to stimulate both antibody production and T-cell mediated immunity (specifically CD4+ and CD8+ T cells) against tumor cells. Clinical evaluation has primarily focused on patients with resected or advanced malignant melanoma, where it has demonstrated significant immunogenicity and a favorable safety profile.
- Other names
- NY-ESO-1 ISCOM vaccineNY-ESO1 ISCOM vaccineNY-ESO 1 ISCOM vaccineNY-ESO-1 protein with ISCOMATRIX adjuvantNY-ESO1 protein with ISCOMATRIX adjuvantNY-ESO 1 protein with ISCOMATRIX adjuvant
02
Targets
CTAG2 (Cancer/testis antigen 2)NY-ESO-1 (New york esophageal squamous cell carcinoma 1)
Beyond the preview
Go deeper on NY-ESO-1 ISCOMATRIX vaccine (Ludwig Cancer Research).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NY-ESO-1 ISCOMATRIX vaccine (Ludwig Cancer Research).